Skip to main content

Table 2 Association of clinical and genetic factors with overall survival

From: Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma

Factor

Group

n

Median survival (d)

p value

Age (y)

> 70

20

660 (413–876)

0.00030

≤ 70

8

333 (105–432)

 

Sex

Male

17

475 (385–735)

0.39

Female

11

412 (175–841)

 

Pre-KPS

> 70

16

409 (314–611)

0.060

≤ 70

12

689 (432–881)

 

EOR

Gross total resection

25

475 (406–689)

0.50

Partial resection

3

432 (105-NA)

 

BCNU wafer

No

19

660 (381–876)

0.11

Yes

9

441 (149–611)

 

Bevacizumab

No

20

453.5 (335–674)

0.75

Yes

8

565 (314–881)

 

Region 1

Methylated

13

674 (406–876)

0.27

Unmethylated

8

422 (105–881)

 

Region 2

Methylated

13

841 (413–961)

0.0026

Unmethylated

8

363 (105–660)

 

Region 3

Methylated

3

876 (406-NA)

0.65

Unmethylated

18

521.5 (331–735)

 
  1. Pre-KPS Preoperative Karnofsky Performance Status